Sirtex Medical

Sirtex Medical produced another record quarter of dose sales, up 37% over the prior period ending 31 September. Sirtex’s sole product, SIR-Spheres microspheres, an innovative form of radiotherapy to treat liver cancer, performed particularly well in the critical US market, where dose sales rose 42%. Despite this impressive result, considerable future growth remains possible. SIR-Spheres are still considered a ‘last line’ treatment for liver cancer, used by around 1% of possible patients. There remains a vast market of potential customers. Sirtex is working furiously to complete clinical trials required to prove the value of its solution as an alternative,...

Sirtex Medical produced another record quarter of dose sales, up 37% over the prior period ending 31 September. Sirtex’s sole product, SIR-Spheres microspheres, an innovative form of radiotherapy to treat liver cancer, performed particularly well in the critical US market, where dose sales rose 42%.

{{content.question}}

{{ twilioFailed ? 'SMS Code Failed to Send…' : 'SMS Code Sent…' }}

Hi {{ user.FirstName }}

Looks like you've already taken a free trial

Please enter your payment details

We have sent you a code via SMS to {{user.DayPhone}}

please enter this code below to activate your membership

We cannot send you a code via SMS to {{user.DayPhone}}

If you didn't receive SMS code please

SMS code cannot be sent due to: {{ twilioStatus }}

Please select one of the options below:

Looks you are already a member. Please enter your password to proceed

Please untick this box when using a public or shared device


Verify your mobile number to unlock a FREE trial

Please sign up for full access

Updating information

Please wait ...

  • Mastercard
  • Visa
Mastercard

The email address you entered is registered with InvestSMART.

Please login or select "Don't know password"

Please untick this box when using a public or shared device


Register as a new member

(using a different email)

Related Articles